Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.09B
EPS-0.5300
P/E Ratio-10.05
Earnings Date08/06/2026

svra

Property, Plant, and Equipment (Net)

Last Annual Value

100.00K

3-Year CAGR

25%

5-Year CAGR

-9%

10-Year CAGR

-8%

Savara Inc.

Savara Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

SVRA · NASDAQ
CompanyProperty, Plant, and Equipment (Net)
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
100.00K
-28.2%6.5%-18.7% 
15.16M
19.6%12.9%81.1%
884.00K
-42.8%-30.3%17.1%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
1.42M
-13.5%27.3%-13.4%
2.03M
35.6%N/AN/A
42.49M
-7.3%47.5%N/A
6.89M
-5.5%26.9%N/A
20.22M
25.5%49.3%52.9%
PROK logo
ProKidney Corp.
NASDAQ:PROK
54.90M
5.8%34.2%N/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.3249